Gómez-Touriño I, Simón-Vázquez R, Alonso-Lorenzo J, Arif S, Calviño-Sampedro C, González-Fernández Á, Pena-González E, Rodríguez J, Viñuela-Roldán J, Verdaguer J, Cordero O J, Peakman M, Varela-Calvino R
Department of Biochemistry and Molecular Biology, University of Santiago de Compostela, Santiago de Compostela, Spain.
Clin Exp Immunol. 2015 May;180(2):207-17. doi: 10.1111/cei.12572.
Type 1 diabetes results from destruction of insulin-producing beta cells in pancreatic islets and is characterized by islet cell autoimmunity. Autoreactivity against non-beta cell-specific antigens has also been reported, including targeting of the calcium-binding protein S100β. In preclinical models, reactivity of this type is a key component of the early development of insulitis. To examine the nature of this response in type 1 diabetes, we identified naturally processed and presented peptide epitopes derived from S100β, determined their affinity for the human leucocyte antigen (HLA)-DRB1*04:01 molecule and studied T cell responses in patients, together with healthy donors. We found that S100β reactivity, characterized by interferon (IFN)-γ secretion, is a characteristic of type 1 diabetes of varying duration. Our results confirm S100β as a target of the cellular autoimmune response in type 1 diabetes with the identification of new peptide epitopes targeted during the development of the disease, and support the preclinical findings that autoreactivity against non-beta cell-specific autoantigens may have a role in type 1 diabetes pathogenesis.
1型糖尿病是由胰岛中产生胰岛素的β细胞被破坏所致,其特征为胰岛细胞自身免疫。也有报道称存在针对非β细胞特异性抗原的自身反应性,包括针对钙结合蛋白S100β的靶向作用。在临床前模型中,这种类型的反应性是胰岛炎早期发展的关键组成部分。为了研究1型糖尿病中这种反应的本质,我们鉴定了源自S100β的天然加工和呈递的肽表位,确定了它们对人类白细胞抗原(HLA)-DRB1*04:01分子的亲和力,并研究了患者以及健康供体的T细胞反应。我们发现,以干扰素(IFN)-γ分泌为特征的S100β反应性是不同病程的1型糖尿病的一个特征。我们的结果通过鉴定疾病发展过程中靶向的新肽表位,证实S100β是1型糖尿病细胞自身免疫反应的一个靶点,并支持临床前的研究结果,即针对非β细胞特异性自身抗原的自身反应性可能在1型糖尿病发病机制中起作用。